A novel role of fibroblast growth factor-2 and pentosan polysulfate in the pathogenesis of intestinal bleeding in mice.

Pentosan polysulfate (PPS) is a heparin-like polysaccharide that can affect the binding interactions of fibroblast growth factor (FGF-2) with its high-affinity receptors. Patients with angiogenic tumors frequently show high levels of FGF-2 in the circulation. Since FGF-2 is a heparin-binding angiogenic growth factor, PPS has been used successfully to block its activity in patients with angiogenic tumors. However, because of its heparin-like activity, the major toxic effect of PPS is the development of bleeding disorders. The role that circulating FGF-2 plays in the pathogenesis of bleeding disorders in patients treated with PPS is currently unknown. Here we hypothesized that FGF-2 might play a physiological role in the pathogenesis of intestinal bleeding induced by PPS. This hypothesis is supported by previous studies showing that PPS is accumulated in the intestine and that circulating FGF-2 specifically binds to and modulates the angiogenic activity of intestinal submucosal endothelial cells. We used recombinant adenoviral vectors carrying a secreted form of FGF-2 and LacZ control vectors to determine whether high levels of circulating FGF-2 facilitate the development of intestinal bleeding disorders in FVB/N and C57BL/6J mice treated with PPS. We found that PPS, acting together with FGF-2, induced structural changes in intestinal vessels leading to the development of lethal intestinal hemorrhages. These findings might have wider clinical implications for the systemic use of PPS and other heparinoids in the treatment of patients with angiogenic diseases associated with high levels of circulating FGF-2.

[1]  Zvi Fuks,et al.  Endothelial Apoptosis as the Primary Lesion Initiating Intestinal Radiation Damage in Mice , 2001, Science.

[2]  Jeffrey D. Esko,et al.  Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor , 1991, Cell.

[3]  M. Klagsbrun,et al.  A dual receptor system is required for basic fibroblast growth factor activity , 1991, Cell.

[4]  J. Folkman.  Clinical Applications of Research on Angiogenesis , 1995 .

[5]  X. Wu,et al.  Requirement for Anticoagulant Heparan Sulfate in the Fibroblast Growth Factor Receptor Complex* , 1999, The Journal of Biological Chemistry.

[6]  M Stürzl,et al.  Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor. , 2001, Molecular biology of the cell.

[7]  M. Jaye,et al.  Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation , 1994, Cell.

[8]  A. Wellstein,et al.  Vascular leakage in chick embryos after expression of a secreted binding protein for fibroblast growth factors , 2005, Laboratory Investigation.

[9]  D. Gospodarowicz,et al.  Structural characterization and biological functions of fibroblast growth factor. , 1987, Endocrine reviews.

[10]  J. Folkman,et al.  The fate of intravenously administered bFGF and the effect of heparin. , 1989, Growth factors.

[11]  R. Iozzo,et al.  Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. , 2001, The Journal of clinical investigation.

[12]  Robert Walgate,et al.  Proliferation , 1985, Nature.

[13]  L. Dencker,et al.  Preferential localization of 3H-pentosanpolysulphate to the urinary tract in rats. , 1987, Pharmacology & toxicology.

[14]  A. Foli,et al.  Administration of pentosan polysulfate to patients with human immunodeficiency virus-associated Kaposi's sarcoma. , 1993, Journal of the National Cancer Institute.

[15]  P. Ray,et al.  Liver bypass significantly increases the transduction efficiency of recombinant adenoviral vectors in the lung, intestine, and kidney. , 2000, Human gene therapy.

[16]  B. Ewenstein,et al.  Anionic polysaccharides inhibit adhesion of sickle erythrocytes to the vascular endothelium and result in improved hemodynamic behavior. , 1999, Blood.

[17]  A. Forbes,et al.  Heparin, cell adhesion, and pathogenesis of inflammatory bow el disease , 1999, The Lancet.

[18]  R. Giavazzi,et al.  Copyright © American Society for Investigative Pathology Distinct Role of Fibroblast Growth Factor-2 and Vascular Endothelial Growth Factor on Tumor Growth and Angiogenesis , 2022 .

[19]  R. Jain,et al.  Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[20]  A. Wellstein,et al.  Inhibition by pentosan polysulfate (PPS) of heparin-binding growth factors released from tumor cells and blockage by PPS of tumor growth in animals. , 1992, Journal of the National Cancer Institute.

[21]  E. Edelman,et al.  Perlecan is required to inhibit thrombosis after deep vascular injury and contributes to endothelial cell-mediated inhibition of intimal hyperplasia. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[22]  D. Ribatti,et al.  Alterations of blood vessel development by endothelial cells overexpressing fibroblast growth factor‐2 , 1999, The Journal of pathology.

[23]  R. D'Amato,et al.  Strain‐dependent anterior segment neovascularization following intravitreal gene transfer of basic fibroblast growth factor (bFGF) , 2001, The journal of gene medicine.

[24]  M. Raffeld,et al.  Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma , 1994, Nature.

[25]  A. Wellstein,et al.  Tumor growth dependent on Kaposi's sarcoma-derived fibroblast growth factor inhibited by pentosan polysulfate. , 1991, Journal of the National Cancer Institute.

[26]  M. Grossman,et al.  Adenovirus-mediated correction of the genetic defect in hepatocytes from patients with familial hypercholesterolemia , 1993, Somatic cell and molecular genetics.

[27]  P. Ku,et al.  Regulation of basic fibroblast growth factor (bFGF) gene and protein expression following its release from sublethally injured endothelial cells , 1995, Journal of cellular biochemistry.

[28]  P. Ray,et al.  Basic fibroblast growth factor in HIV-associated hemolytic uremic syndrome , 1999, Pediatric Nephrology.

[29]  C. Cho,et al.  Association of heparin with basic fibroblast growth factor, epidermal growth factor, and constitutive nitric oxide synthase on healing of gastric ulcer in rats. , 1999, The Journal of pharmacology and experimental therapeutics.

[30]  J. Soria,et al.  Anticoagulant activities of a pentosane polysulphate: comparison with standard heparin and a fraction of low molecular weight heparin. , 1980, Thrombosis research.

[31]  A. Yayon,et al.  Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis , 1994, Cell.

[32]  A. Cnaan,et al.  Basic fibroblast growth factor among children with diarrhea-associated hemolytic uremic syndrome. , 2002, Journal of the American Society of Nephrology : JASN.

[33]  M. Scully,et al.  Anticoagulant and antiheparin activities of a pentosan polysulphate. , 1983, Thrombosis research.

[34]  A. Yayon,et al.  Effect of Heparin on Tissue Binding Activity of Fibroblast Growth Factor and Heparin-Binding Epidermal Growth Factor in Experimental Colitis in Rats , 2002, Pediatric Research.

[35]  J. Hanfelt,et al.  Phase I trial of orally administered pentosan polysulfate in patients with advanced cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.